Atara Biotherapeutics effects 1:25 reverse stock split effective June 20, 2024

Atara Biotherapeutics, Inc.

Reverse stock split ratio of 1:25 approved by board on June 10, effective June 20.
Common stock begins trading on split-adjusted basis under new CUSIP 046513206.
No fractional shares; cash payment based on closing price prior to effective date.
Stockholders approved proposal at annual meeting on June 10, 2024.
Amendment filed with Delaware Secretary of State.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.